Optimization of pathogenetic therapy in patients with chronic obstructive pulmonary disease combined with ischemic heart disease | Український Медичний Часопис

Krakhmalova E.O.,Tokareva A.Yu.,Kharchenko Yu.E.

Головна
Публікації
Optimization of pathogenetic therapy in patients with chronic obstructive pulmonary disease combined with ischemic heart disease

Optimization of pathogenetic therapy in patients with chronic obstructive pulmonary disease combined with ischemic heart disease

28 вересня 2018

997

Cardiology, Rheumatology

Therapy, General practice

Allergology and Pulmonology

Krakhmalova E.O.

Tokareva A.Yu.

Kharchenko Yu.E.

Спеціальності :

Cardiology, Rheumatology

Therapy, General practice

Allergology and Pulmonology

Резюме

A comparative estimation of the influence of bronchodilators on the clinical symptoms of chronic obstructive pulmonary disease (COPD) and intracardiac hemodynamics in patients with COPD and coronary heart disease (CHD) has been conducted. The results of the study showed the advantage of the use of the long-acting M-cholinolytics (glycopyrronium bromide) against the long-acting β2-adrenergic agonist (formoterol fumarate) in reducing the number of exacerbations, preserving the contractile capacity of the myocardium and inotropic function of the heart, improving the diastolic function of the right ventricle, characterized by normalization (increasing) of the peak of the maximum speed of early diastolic filling and decreasing of the peak of the maximum speed of the atrial diastolic filling which led to the normalization of their relationship. The literature data and the results of our own research suggest that long-acting M-cholinolytics are the drug of choice in patients with COPD and CHD, and also mucolytics (acetylcysteine, ACC®, «Sandoz»), which contributes to lowering the frequency, severity and duration of exacerbations, should be included in the treatment scheme for such patients.

E.O. Krakhmalova, Yu.E. Kharchenko, A.Yu. Tokareva

Key words: chronic obstructive pulmonary disease, ischemic heart disease, long-acting M-cholinolytics, long-acting β2-adrenergic agonists, mucolytics, acetylcysteine, ACC®.

Published: 23.10.2018

References:

Dzyublik Ya.A. (2016) Dvoynaya bronhodilatatsiya v profilaktike obostreniy hronicheskogo obstruktivnogo zabolevaniya legkih. Perspektivyi, otkryityie issledovaniem FLAME. Astma ta alergIya, 4: 67–68.
Krahmalova E.O., Harchenko Yu.E., Kolesnikova E.N. (2014) Vliyanie farmakoterapii hronicheskogo obstruktivnogo zabolevaniya legkih na soputstvuyuschuyu kardiovaskulyarnuyu patologiyu. Ukr. ter. zhurn., 1: 79–84.
Krakhmalova O.O., Hetman O.A., Kharchenko Yu.Ie., Izmailova O.V. (2017) Dynamika ultrazvukovykh parametriv diastolichnoi ta systolichnoi funktsii sertsia u khvorykh na KhOBL ta suputniu IKhS v zalezhnosti vid vyboru bazysnoi terapii KhOBL ta naiavnosti pulmonalnoi reabilitatsii. Ukr. pulmonol. zhurn., 4: 30–34.
Maev I.V., Busarova G.A. (2003) Mukoliticheskie sredstva v terapii hronicheskoy obstruktivnoy bolezni legkih. Lech. vrach, 1: 25–32.
Ostrovskyi M.M., Varunkiv O.I. (2015) Tiotropiiu bromid — efektyvnist, bezpechnist, potribnist pry KhOBL. Ukr. pulmonol. zhurn., 1: 32–34.
Provotorov V.M., Kotochigova T.V. (2011) Farmakoterapiya hronicheskoy obstruktivnoy bolezni legkih i hronicheskoy serdechnoy nedostatochnosti. Molodoy uchenyiy, 6(2): 187–189.
Campbell S.C., Criner G.J., Levine B.E. et al. (2007) Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther., 20(5): 571–579.
Casaburi R., Kukafka D., Cooper C.B. et al. (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest, 127(3): 809–817.
Casas A., Troosters T., Garcia-Aymerich J. et al.; members of the CHRONIC Project (2006) Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J., 28(1): 123–130.
Cooper C.B. (2009) Airflow obstruction and exercise. Respir. Med., 103(3): 325–334.
Decramer M., Celli B., Tashkin D.P. et al. (2004) Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD, 1(2): 303–312.
Falk J.A., Kadiev S., Criner G.J. et al. (2008) Cardiac Disease in Chronic Obstructive Pulmonary Disease. Proc. Am. Thorac. Soc., 5(4): 543–548.
Halpin D., Decramer M., Celli B. et al. (2012) Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading, European Respiratory Society, Vienna, 853288.
Hasegawa M., Makita H., Nasuhara Y. et al. (2009) Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax, 64(4): 332–338.
Hui K.P., Hewitt A.B. (2003) A simple pulmonary rehabilitation program improves health outcomes and reduces hospital utilization in patients with COPD. Chest, 124(1): 94–97.
Kerwin E., Hébert J., Gallagher N. et al. (2012) Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 40(5): 1106–1114.
Khindri S., Sabo R., Harris S. et al. (2011) Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm. Med., 11: 31.
Löfdahl C.G., Postma D.S., Pride N.B. et al. (2007) Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J., 29(6): 1115–1119.
Maclay J.D., MacNee W. (2013) Cardiovascular disease in COPD: mechanisms. Chest, 143(3): 798–807.
Miravitlles M., Beeh K.-M., Altman P. (2014) Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clin. Invest. (Lond.), 4(12): 1095–1111.
Montuschi P., Malerba M., Macis G. et al. (2016) Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov. Today, 21(11): 1820–1827.
Nici L., Donner C., Wouters E. et al.; ATS/ERS Pulmonary Rehabilitation Writing Committee (2006) American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med., 173(12): 1390–1413.
Niewoehner D.E. (2010) Clinical practice. Outpatient management of severe COPD. N. Engl. J. Med., 362(15): 1407–1416.
Reisner C., Fabbri L.M., Kerwin E.M. et al. (2017) Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir. Res., 18(1): 158.
Sidney S., Sorel M., Quesenberry C.P.Jr. et al. (2005) COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest, 128(4): 2068–2075.
Tashkin D.P., Fabbri L.M. (2010) Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir. Res., 11: 149.
Vogelmeier C.F., Criner G.J., Martinez F.J. et al. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am. J. Respir. Crit. Care Med., 195(5): 557–582.